Table 1.
Characteristics of patients aged 16 years from the validation cohort
| Men (n=362 769) | Women (n=384 231) | ||
|---|---|---|---|
| Familial hypercholesterolaemia diagnosis | 485 (0·1%) | 734 (0·2%) | |
| Age, years | 51·2 (15·7) | 52·4 (17·3) | |
| Age during cholesterol measurement, years | 54·6 (15·3) | 56·5 (16·8) | |
| History of premature myocardial infarction* | 12 712 (3·5%) | 4333 (1·1%) | |
| Ethnicity | |||
| White, white British, or other white | 189 239 (52·2%) | 210 914 (54·9%) | |
| Asian, Asian British, or other Asian | 5361 (1·5%) | 6011 (1·6%) | |
| Black, black British, African, or Caribbean | 9231 (2·5%) | 11 204 (2·9%) | |
| Mixed or multiple ethnic groups | 17 454 (4·8%) | 16 847 (4·4%) | |
| Other ethnic group | 12 137 (3·3%) | 13 320 (3·5%) | |
| Unknown or not recorded | 129 347 (35·7%) | 125 935 (32·8%) | |
| Lipid profile | |||
| Highest total cholesterol recorded, mmol/L | 5·6 (1·2) | 5·8 (1·3) | |
| Highest LDL cholesterol recorded, mmol/L | 3·2 (1·1) | 3·2 (1·0) | |
| Triglycerides during cholesterol measurement, mmol/L† | 2·2 (1·7) | 1·7 (1·2) | |
| Lipid-lowering drug usage at time of cholesterol measurement | |||
| Prescribed fibrate, bile acid sequestrant, or nicotinic acid | 885 (0·2%) | 731 (0·2%) | |
| Prescribed low-potency statin | 4739 (1·3%) | 3658 (1·0%) | |
| Prescribed medium-potency statin | 16 669 (4·6%) | 13 431 (3·5%) | |
| Prescribed high-potency statin | 5597 (1·5%) | 3848 (1·0%) | |
| Family history | |||
| Family history of familial hypercholesterolaemia | 949 (0·3%) | 1526 (0·4%) | |
| Family history of raised cholesterol | 2554 (0·7%) | 3718 (1·0%) | |
| Family history of myocardial infarction | 11 300 (3·1%) | 13 499 (3·5%) | |
| Secondary causes of high cholesterol at time of cholesterol measurement | |||
| Diabetes diagnosis | 54 680 (15·1%) | 44 834 (11·7%) | |
| Chronic kidney disease diagnosis | 32 551 (9·0%) | 43 911 (11·4%) | |
Data are n (%) or mean (SD).
*
Premature is defined as younger than 55 years in men and younger than 60 years in women.
†
Data missing for 116 532 (15·6%) of 747 000 participants.